Skip to content
Optellum
  • About us
    • Vision
    • Team
    • Advisors
    • Careers
  • Products & solutions
    • Incidental management
    • Lung Cancer Prediction AI
  • Resources
    • Case studies
    • Clinical Validation
    • Customer Support
  • News & Events
    • In the Media
  • Contact
    • General inquiries
    • Newsletter
    • Contact sales
Menu Close
  • About us
    • Vision
    • Team
    • Advisors
    • Careers
  • Products & solutions
    • Incidental management
    • Lung Cancer Prediction AI
  • Resources
    • Case studies
    • Clinical Validation
    • Customer Support
  • News & Events
    • In the Media
  • Contact
    • General inquiries
    • Newsletter
    • Contact sales

News & Events

Biopharma AI Collaborations Driving Innovative Change in Drug Development

  • Post author:Rhiannon Lassiter
  • Post published:September 13, 2021
  • Post category:Media

BioSpace

Read more articles

Previous PostBiopharma AI Collaborations Driving Innovative Change in Drug Development
Next PostPRESS RELEASE: Optellum Appoints Jason Pesterfield as CEO to Drive Commercial Growth in the USA

You Might Also Like

Read more about the article PRESS RELEASE:  CMS assigns new technology payment classification for Optellum’s Lung Cancer Prediction score

PRESS RELEASE: CMS assigns new technology payment classification for Optellum’s Lung Cancer Prediction score

June 28, 2022
Read more about the article Top Story GE Healthcare, Optellum partner up for AI-driven lung cancer diagnosis

Top Story GE Healthcare, Optellum partner up for AI-driven lung cancer diagnosis

November 26, 2021
Read more about the article EIT Health partners unite to advance lung cancer diagnosis

EIT Health partners unite to advance lung cancer diagnosis

December 10, 2021
  • Back to News & Events

Recent Posts

  • Jason Pesterfield, Optellum CEO, appears on Houston Innovators podcast
  • Lung Cancer Awareness Month: Optellum’s AI platform demonstrates a vital role in efficient diagnosis to improve lung cancer survival rates
  • Pulmonary advances and clinical collaborations at CHEST 2022
  • WABIP comes to Europe to showcase the best in lung health
  • Optellum, AI Lung Cancer Diagnosis Innovator,
    Secures $14M Series A Funding to Accelerate Expansion

Our Mission

Optellum was founded so that every lung disease patient is diagnosed and treated at the earliest possible stage, and cured.  Our vision is to redefine early intervention of diseases like lung cancer, by enabling every clinician, in every hospital, to make the right decisions and give their patients the best chance to fight back.

Optellum Ltd.

  • Oxford Centre for Innovation
    Oxford, OX1 1BY
    United Kingdom
  • info@optellum.comOpens in your application

Optellum Inc.

  • TMC Innovation Institute
    2450 Holcombe Blvd, Suite X
    Houston, TX 77021
    United States

Pages

  • About us
    • Vision
    • Team
    • Advisors
    • Careers
  • Products & solutions
    • Incidental management
    • Lung Cancer Prediction AI
  • Resources
    • Case studies
    • Clinical Validation
    • Customer Support
  • News & Events
    • In the Media
  • Contact
    • General inquiries
    • Newsletter
    • Contact sales

Follow Us

  • Opens in a new tab
  • Opens in a new tab

Certifications

Copyright 2023 - Optellum Ltd | Privacy Policy
Manage Cookie Consent
We use cookies to optimize our website and our service.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}